Lithium Ion

Lithium Ion

SCHEMBL9984178

CC(C)(C)c1ccc(N2CCN(CCCC(=O)[O-])CC2)cc1.[Li+]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 12/20 0.50
DRD2 P14416 11/20 0.50
HRH3 Q9Y5N1 3/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CACNA1G O43497 1/20 0.46
HTR1A P08908 3/20 0.46
HTR7 P34969 2/20 0.46
PDE4B Q07343 1/20 0.46
PDE7A Q13946 1/20 0.46
DRD3 P35462 2/20 0.46
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HRH1 P35367 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL9984309 0.95 DRD4 (0.48) DRD4DRD2HRH3ALDH1A1LMNA
Lithium Ion SCHEMBL9983843 0.92 MEN1 (0.47) DRD4DRD2HRH3ALDH1A1LMNA
Lithium Ion SCHEMBL9983926 0.87 DRD2 (0.59) DRD4DRD2HTR1AHTR7DRD3
SCHEMBL12041897 0.86 ALDH1A1 (0.52) DRD4DRD2HRH3ALDH1A1LMNA
SCHEMBL381362 0.85 ALDH1A1 (0.51) DRD4DRD2HRH3ALDH1A1LMNA
SCHEMBL12042061 0.82 DRD2 (0.50) DRD4DRD2HRH3ALDH1A1LMNA
SCHEMBL9984306 0.81 DRD2 (0.49) DRD4DRD2HRH3ALDH1A1LMNA
SCHEMBL460673 0.81 HRH3 (0.50) DRD4DRD2HRH3ALDH1A1LMNA
SCHEMBL12041659 0.81 HTR1A (0.51) DRD4DRD2HRH3ALDH1A1LMNA
Lithium Ion SCHEMBL463205 0.81 HRH3 (0.46) HRH3ALDH1A1LMNAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 US disclosed
EP-2408742-B1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INT BV (NL) 2014-09-03 EP disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE ACHE, ABCB11, MPO DRD4 3926/4885DRD2 3527/4885HRH3 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.